Can I Take Resveratrol with PT-141 (Bremelanotide)?

What PT-141 (Bremelanotide) Actually Does

Bremelanotide is a synthetic melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi. It is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women and used off-label for erectile dysfunction in men. The drug binds melanocortin receptors MC3R and MC4R in the central nervous system rather than acting on vascular tissue the way phosphodiesterase-5 inhibitors do.

Mechanism at the Melanocortin Receptor

MC4R activation in the paraventricular nucleus of the hypothalamus increases dopaminergic signaling, which is thought to be the primary driver of increased sexual desire. The peptide does not require sexual stimulation to initiate its effect, which distinguishes it from agents like sildenafil.

The FDA prescribing information for Vyleesi states the recommended dose is 1.75 mg injected subcutaneously approximately 45 minutes before anticipated sexual activity, with a maximum of one dose in 24 hours and no more than one dose in any 8-hour period. The most common adverse effects in the phase 3 RECONNECT trials (N=1,267 across two trials) were nausea (40%), flushing (20%), and injection-site bruising (11%). (1)

Pharmacokinetics at a Glance

After a single 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour. Its elimination half-life is about 2.7 hours. The drug is primarily metabolized via hydrolysis of the amide bonds in the peptide backbone, not through the cytochrome P450 system. However, the FDA label notes that bremelanotide is a weak inhibitor of CYP1A2, CYP2B6, and CYP3A4 itself, which matters when you add a supplement that shares the same enzymatic pathway. (2)

What Resveratrol Does and Why the CYP System Matters

Resveratrol (3,5,4-trihydroxystilbene) is a polyphenol produced by grapes, Japanese knotweed (Polygonum cuspidatum), and peanuts in response to stress. Typical supplemental doses range from 150 mg to 1,000 mg per day, though clinical trials for cardiovascular outcomes have used doses from 10 mg up to 5,000 mg. The compound is widely marketed for longevity, cardiovascular health, and, more recently, hormonal balance in perimenopausal women.

CYP3A4 Inhibition: The Core Pharmacokinetic Concern

The most clinically relevant interaction concern is CYP3A4 inhibition. Research published in Drug Metabolism and Disposition demonstrated that resveratrol inhibits CYP3A4 activity in human liver microsomes, with an IC50 of approximately 25 to 40 micromolar depending on the substrate used. A 500 mg oral dose produces peak plasma concentrations in the low-micromolar range, which is sufficient to partially inhibit intestinal CYP3A4. (3)

While bremelanotide itself is metabolized primarily by peptide hydrolysis, its prescribing information flags it as a weak CYP3A4 inhibitor. Two CYP3A4 inhibitors taken together could produce additive suppression of this enzyme, slowing the clearance of any co-administered substrates and, to a lesser degree, each other.

CYP1A2 and CYP2C9: Supporting Concerns

Resveratrol also inhibits CYP1A2 and CYP2C9 in vitro. (4) These enzymes are not primary metabolic routes for bremelanotide, but the overlap is worth noting if the patient is also taking other medications (for example, caffeine or warfarin) that depend on those pathways.

Bioavailability Variability

Resveratrol has notoriously poor oral bioavailability, typically 1% or less after a standard dose due to extensive first-pass glucuronidation and sulfation in the gut wall and liver. (5) This means the systemic CYP3A4 inhibition from a moderate resveratrol dose is limited, but the intestinal wall inhibition is disproportionately larger and affects oral drugs more than injectable ones. Since bremelanotide is subcutaneous, it bypasses the gut entirely, which reduces but does not eliminate the pharmacokinetic interaction risk.

The Phytoestrogenic Question

Resveratrol binds estrogen receptors alpha and beta (ERalpha and ERbeta), acting as a selective estrogen receptor modulator (SERM). Its affinity for ERbeta is approximately 7,000-fold lower than estradiol, but at the gram-scale doses some users take, receptor occupancy may be non-trivial. (6)

Why Estrogenicity Matters for HSDD

HSDD in premenopausal women is associated with reduced testosterone and, in some patients, shifts in estrogen-to-androgen ratios. Estrogen modulates melanocortin receptor expression in the hypothalamus. Specifically, ERbeta activation has been shown in animal models to downregulate MC4R density in the paraventricular nucleus. (7) If resveratrol exerts even mild ERbeta agonism, it could theoretically blunt the density or sensitivity of the very receptors bremelanotide is trying to activate.

This is a pharmacodynamic concern, and direct human clinical data do not yet exist for this specific combination. The mechanism is biologically plausible, not confirmed.

Resveratrol in Women's Hormonal Health: What the Trials Show

A 12-week double-blind RCT published in Menopause (N=80 postmenopausal women) found that resveratrol 75 mg twice daily improved menopausal symptom scores and endothelial function without significantly raising estradiol levels. (8) The absence of significant estradiol elevation suggests the estrogenic effect operates primarily through receptor modulation rather than increasing circulating estrogen. That distinction is important: receptor-level activity can still influence the downstream signaling environment that bremelanotide enters, even without raising serum E2.

Blood Pressure: A Shared Concern

Bremelanotide carries a labeled warning for transient blood pressure increases. In the RECONNECT trials, mean systolic BP increased by approximately 2 mmHg and mean diastolic BP by 1 mmHg after the 1.75 mg dose, with isolated readings exceeding 40 mmHg systolic over baseline in a small number of subjects. The label recommends against use in patients with uncontrolled hypertension or cardiovascular disease. (1)

Resveratrol, by contrast, generally lowers blood pressure. A meta-analysis of 17 RCTs (N=681) found that resveratrol supplementation reduced systolic BP by 2.00 mmHg (95% CI: 0.10 to 3.90 mmHg, P<0.05). (9) In one sense, the blood-pressure effects may partially offset each other. But the directions of effect vary by timing and dose, and clinicians should not assume the pairing is hemodynamically neutral without measuring.

Nausea Overlap

Nausea affects roughly 40% of bremelanotide users at the approved dose. Resveratrol at doses above 1,000 mg per day produces GI side effects, including nausea and diarrhea, in a meaningful proportion of users. Taking high-dose resveratrol within 1 to 2 hours of a bremelanotide injection may worsen the nausea burden. This is not a drug-drug interaction in the classical pharmacokinetic sense, but it is clinically relevant for tolerability.

Practical Dosing and Timing Guidance

The following timing framework is based on bremelanotide's pharmacokinetic profile (half-life approximately 2.7 hours, peak at approximately 1 hour) and resveratrol's CYP inhibitory onset (measurable within 1 hour of an oral dose, largely resolved by 6 to 8 hours post-ingestion based on in-vitro half-life data for resveratrol-CYP complexes).

Recommended Approach

1. Take your regular resveratrol dose in the morning if you anticipate using bremelanotide in the afternoon or evening. A 6-hour gap minimizes concurrent peak CYP inhibition.
2. Do not take resveratrol within 2 hours before or 2 hours after the bremelanotide injection if you cannot plan a longer separation.
3. If you use bremelanotide infrequently (once weekly or less), the cumulative pharmacokinetic risk from occasional resveratrol co-administration is low given bremelanotide's short half-life.
4. At resveratrol doses below 250 mg per day, the CYP3A4 inhibition is likely sub-clinical for an injectable peptide with a 2.7-hour half-life.
5. At resveratrol doses of 500 mg per day or higher, discuss the combination with your prescriber before your first bremelanotide dose.

Who Should Be More Cautious

Patients taking other CYP3A4-sensitive medications alongside both agents face a higher risk of accumulation effects. Common CYP3A4 substrates with narrow therapeutic indices include tacrolimus, cyclosporine, certain statins (simvastatin, lovastatin), and some HIV antiretrovirals. If you are on any of these, the additive CYP inhibition from bremelanotide plus resveratrol warrants a pharmacist review.

Women using bremelanotide off-label with concurrent hormonal therapy (including phytoestrogens from soy or red clover) should flag resveratrol use to their prescriber, given the additive estrogenic receptor activity discussed above.

What the Guidelines Say (and Do Not Say)

No major clinical guideline from the American Urological Association, the Endocrine Society, or the North American Menopause Society specifically addresses bremelanotide-resveratrol co-administration as of the 2025 review date. The Vyleesi prescribing information lists naltrexone as a drug whose AUC is reduced by approximately 35% when co-administered with bremelanotide, which demonstrates that the drug does have pharmacokinetic interaction potential even though its own metabolism is primarily non-CYP. (2)

The North American Menopause Society position statement on nonhormonal therapies (2023) notes: "Phytoestrogens, including resveratrol, have biologically plausible mechanisms for modifying hypothalamic estrogen receptor activity, but evidence from adequately powered trials is insufficient to support specific dosing recommendations alongside pharmacological agents." (10)

That framing aligns with the current state of evidence: mechanism exists, human trial data for this specific pairing do not.

Monitoring Checklist If You Take Both

Regular monitoring reduces the unknowns. The following parameters are worth tracking if you continue both agents:

• Blood pressure at baseline and 90 minutes after the first combined use
• Nausea severity on a simple 0-to-10 scale after each bremelanotide dose
• Sexual desire response over 4 to 8 weeks to detect any attenuation of bremelanotide effect
• Liver enzymes (ALT, AST) at 3-month intervals if using resveratrol at 500 mg or higher daily, given resveratrol's mild hepatotoxicity signal at high doses (11)

No laboratory test directly measures CYP3A4 activity in clinical practice, so the pharmacokinetic risk cannot be quantified with standard panels. The clinical surrogate is whether bremelanotide's effects (onset, intensity, duration) change after adding resveratrol.

A Note on Off-Label Use in Men

Men using bremelanotide off-label for erectile dysfunction face the same pharmacokinetic considerations described above. The androgen-receptor and melanocortin-receptor crosstalk in male sexual physiology is different from the female HSDD context, and resveratrol's phytoestrogenic activity is less likely to modulate MC4R density in men at supplemental doses. The CYP3A4 timing concern applies equally regardless of sex.

Resveratrol Dose Matters More Than People Realize

A 150 mg daily dose of resveratrol (common in mass-market supplements) behaves very differently from 500 mg or 1,000 mg. A study in Cancer Prevention Research (N=40) found that a single 5,000 mg resveratrol dose reduced plasma levels of certain CYP3A4 substrates by up to 50%, while a 500 mg dose produced measurable but smaller reductions. (12) Dose-specific communication with your clinician is more useful than a blanket "safe or not safe" answer.